fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

By John F. Heerdink, Jr.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, announced this week that management will host a virtual event to highlight interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas on August 19, 2021 at 4:30 p.m. ET.

The live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website beginning approximately two hours after the event.




YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us